Navigation Links
Sanford-Burnham research advances to patient studies at TRI
Date:3/6/2012

ORLANDO, Fla., March 6, 2012 Discoveries made in the laboratories of Sanford-Burnham Medical Research Institute at Lake Nona will, for the first time, advance to the clinical research stage involving human studies at the Florida Hospital Sanford-Burnham Translational Research Institute for Metabolism and Diabetes (TRI). The research will focus on orexin, an appetite-inducing hormone produced in the brain, which appears to resolve obesity without changes in food consumption or elevation in physical activity. This research is an example of the translational research focus at Sanford-Burnham and the TRI advancing science from laboratory bench to patient bedside. The studies will provide insight into individual responses and contribute to the development of personalized therapies for treating metabolic diseases - a focus area for both TRI and Sanford-Burnham.

Appetite-suppressing drugs have traditionally been the basis of weight-loss treatments since obesity is thought to be caused by excessive energy intake and low physical activity. However, appetite suppressants can produce unacceptable side effects and, after the treatment ends, patients usually regain more weight than they lost. Recent data indicate that orexin leads to weight loss by releasing excess energy as heat instead of storing it.

"At the center of our study," said Devanjan Sikder, D.V.M., Ph.D., assistant professor in Sanford-Burnham's Diabetes and Obesity Research Center, "is an anti-obesity strategy that does not rely on reducing food intake. Instead, we focus on the energy expenditure and feeding-inducing properties of orexin." He added, "My team has discovered that orexin activates calorie-burning brown fat, which we consider to be 'good' fat, and evidence strongly suggests that human obesity can arise from brown fat dysfunction."

Brown fat burns high quantities of sugar and fat, a process that is designed by nature to moderate body temperature in babies, who have large numbers of brown fat cells. By finding a way to activate brown fat in adults, calories, which otherwise would be stored as unwanted white fat, can be burned. Orexin deficiency is associated with obesity in both animals and humans, while high orexin levels correlate with leanness.

"Advancing this orexin research to the TRI is a crucial first step in translating fundamental research at Sanford-Burnham to the clinical phase," said Steven Smith, M.D., scientific director of the TRI and co-director of translational research for Sanford-Burnham's Diabetes and Obesity Research Center. "At the TRI we will conduct proof-of-concept experiments to validate this new drug target and begin to test it for safety and efficacy."

So far, orexin has only been tested in mouse models, where it has been shown to reduce fat by 50 percent, even under conditions of caloric excess. The fat loss is due to an elevation in the metabolic rate. During the study at the TRI, scientists will conduct clinical testing to assess orexin's mode of action, efficacy, and how it works in the human body, as well as evaluate the hormone's acute effect in stimulating energy expenditure.

When it opens in March 2012, the TRI's new 54,000 sq. ft. facility in Orlando, Florida, will contain a research clinic, imaging technology, a biorepository for sample collection and storage, as well as several other resources for metabolic studies. But the facility's highlight will be the calorimeter rooms - small dormitory-style rooms that will allow TRI staff to measure fat and carbohydrate oxidation and energy expenditure as a person goes about his or her normal life. To make the best use of the generated data, the TRI is also building a superior informatics platform to collect and analyze their own research data, as well as personal and sample information for thousands of Florida Hospital patients. This database will help TRI, Florida Hospital and Sanford-Burnham scientists to better correlate patient information with data collected through laboratory research in Sanford-Burnham's metabolomics laboratory.


'/>"/>

Contact: Deborah Robison
drobison@sanfordburnham.org
407-745-2073
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Related medicine news :

1. Sanford-Burnham and Florida Hospital review obesity research progress with Takeda Pharmaceutical
2. Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida
3. Sanford-Burnham researchers find molecular switch that allows melanoma to resist therapy
4. Scripps Health and Sanford-Burnham to collaborate to advance new cancer treatments
5. Dr. Kristiina Vuori Promoted to President of Sanford-Burnham Medical Research Institute
6. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
7. Chinese Minister of Health to hold US meeting to improve cancer research collaboration
8. Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder
9. Notre Dames Bengal Bouts participants aid in concussion research
10. NIH asthma outcome measures aim to maximize research investments, reduce disparities
11. Standardized outcome measures proposed for asthma clinical research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: